vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and PLAYSTUDIOS, Inc. (MYPS). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $55.4M, roughly 1.1× PLAYSTUDIOS, Inc.). PLAYSTUDIOS, Inc. runs the higher net margin — -24.7% vs -70.9%, a 46.2% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -18.3%). PLAYSTUDIOS, Inc. produced more free cash flow last quarter ($3.6M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -15.6%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
CTKB vs MYPS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $55.4M |
| Net Profit | $-44.1M | $-13.7M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | -17.7% |
| Net Margin | -70.9% | -24.7% |
| Revenue YoY | 8.1% | -18.3% |
| Net Profit YoY | -557.1% | 38.9% |
| EPS (diluted) | — | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $55.4M | ||
| Q3 25 | $52.3M | $57.6M | ||
| Q2 25 | $45.6M | $59.3M | ||
| Q1 25 | $41.5M | $62.7M | ||
| Q4 24 | $57.5M | $67.8M | ||
| Q3 24 | $51.5M | $71.2M | ||
| Q2 24 | $46.6M | $72.6M | ||
| Q1 24 | $44.9M | $77.8M |
| Q4 25 | $-44.1M | $-13.7M | ||
| Q3 25 | $-5.5M | $-9.1M | ||
| Q2 25 | $-5.6M | $-2.9M | ||
| Q1 25 | $-11.4M | $-2.9M | ||
| Q4 24 | $9.6M | $-22.4M | ||
| Q3 24 | $941.0K | $-3.1M | ||
| Q2 24 | $-10.4M | $-2.6M | ||
| Q1 24 | $-6.2M | $-567.0K |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | -17.7% | ||
| Q3 25 | -17.6% | -13.6% | ||
| Q2 25 | -23.3% | -5.9% | ||
| Q1 25 | -36.1% | -4.4% | ||
| Q4 24 | 5.2% | -33.1% | ||
| Q3 24 | -8.2% | -6.7% | ||
| Q2 24 | -18.3% | -5.5% | ||
| Q1 24 | -23.9% | -2.2% |
| Q4 25 | -70.9% | -24.7% | ||
| Q3 25 | -10.5% | -15.8% | ||
| Q2 25 | -12.2% | -5.0% | ||
| Q1 25 | -27.5% | -4.6% | ||
| Q4 24 | 16.8% | -33.1% | ||
| Q3 24 | 1.8% | -4.3% | ||
| Q2 24 | -22.4% | -3.6% | ||
| Q1 24 | -13.8% | -0.7% |
| Q4 25 | — | $-0.12 | ||
| Q3 25 | — | $-0.07 | ||
| Q2 25 | — | $-0.02 | ||
| Q1 25 | — | $-0.02 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $104.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $227.9M |
| Total Assets | $461.5M | $290.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $104.9M | ||
| Q3 25 | $93.3M | $106.3M | ||
| Q2 25 | $75.5M | $112.9M | ||
| Q1 25 | $95.3M | $107.1M | ||
| Q4 24 | $98.7M | $109.2M | ||
| Q3 24 | $162.3M | $105.2M | ||
| Q2 24 | $177.9M | $106.3M | ||
| Q1 24 | $168.8M | $127.0M |
| Q4 25 | $341.7M | $227.9M | ||
| Q3 25 | $378.6M | $238.9M | ||
| Q2 25 | $377.6M | $245.3M | ||
| Q1 25 | $379.6M | $244.1M | ||
| Q4 24 | $395.7M | $244.7M | ||
| Q3 24 | $385.5M | $265.2M | ||
| Q2 24 | $389.1M | $263.6M | ||
| Q1 24 | $392.6M | $288.4M |
| Q4 25 | $461.5M | $290.6M | ||
| Q3 25 | $494.9M | $299.2M | ||
| Q2 25 | $493.3M | $316.2M | ||
| Q1 25 | $482.6M | $313.8M | ||
| Q4 24 | $499.5M | $323.0M | ||
| Q3 24 | $491.2M | $330.6M | ||
| Q2 24 | $483.7M | $333.4M | ||
| Q1 24 | $492.1M | $357.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $3.7M |
| Free Cash FlowOCF − Capex | $-1.8M | $3.6M |
| FCF MarginFCF / Revenue | -2.9% | 6.5% |
| Capex IntensityCapex / Revenue | 1.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $3.7M | ||
| Q3 25 | $-3.9M | $5.7M | ||
| Q2 25 | $108.0K | $13.6M | ||
| Q1 25 | $-125.0K | $3.3M | ||
| Q4 24 | $2.0M | $11.6M | ||
| Q3 24 | $13.2M | $14.6M | ||
| Q2 24 | $6.2M | $14.5M | ||
| Q1 24 | $4.0M | $5.0M |
| Q4 25 | $-1.8M | $3.6M | ||
| Q3 25 | $-4.6M | $5.4M | ||
| Q2 25 | $-1.5M | $13.2M | ||
| Q1 25 | $-974.0K | $3.2M | ||
| Q4 24 | $1.1M | $11.5M | ||
| Q3 24 | $12.2M | $13.9M | ||
| Q2 24 | $5.2M | $12.8M | ||
| Q1 24 | $3.4M | $3.6M |
| Q4 25 | -2.9% | 6.5% | ||
| Q3 25 | -8.7% | 9.3% | ||
| Q2 25 | -3.2% | 22.3% | ||
| Q1 25 | -2.3% | 5.1% | ||
| Q4 24 | 1.9% | 16.9% | ||
| Q3 24 | 23.7% | 19.6% | ||
| Q2 24 | 11.0% | 17.6% | ||
| Q1 24 | 7.6% | 4.6% |
| Q4 25 | 1.6% | 0.2% | ||
| Q3 25 | 1.3% | 0.5% | ||
| Q2 25 | 3.5% | 0.7% | ||
| Q1 25 | 2.0% | 0.2% | ||
| Q4 24 | 1.6% | 0.2% | ||
| Q3 24 | 2.0% | 0.9% | ||
| Q2 24 | 2.3% | 2.4% | ||
| Q1 24 | 1.3% | 1.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
MYPS
Segment breakdown not available.
